MetaCap

AN2 Therapeutics (ANTX) vs Cartesian Therapeutics (RNAC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AN2 Therapeutics (ANTX) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 366.1% versus a loss of 15.2%. AN2 Therapeutics is the larger company by market cap ($192.8 million vs $187.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANTX+366.06%RNAC-15.19%
+501%+228%-44%
Nov 21, 20251 yearNov 20, 2026
ANTX-67.01%RNAC-85.17%
+87%-8%-102%
Mar 21, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANTX versus RNAC key metrics
MetricANTXRNAC
Share price$5.08$6.14
Market cap$192.75M$187.29M
1-day change-2.68%+4.24%
YTD return+345.61%-14.84%
1-year return+366.06%-15.19%
5-year return—-92.94%
EPS (TTM)$-0.91$-4.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.80M
Revenue growth (YoY)—-92.81%
Net income (latest FY)$-35.17M$-130.30M
Operating margin—-5127.10%
Net margin—-4658.63%
52-week high$7.19$11.00
52-week low$1.00$5.60
Distance from 52-week high-29.35%-44.18%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.17%+448.37%
Average volume289.29K139.65K
Shares outstanding37.94M30.50M
Employees2175
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANTX has outperformed RNAC by 381.2 percentage points over the past year.

About AN2 Therapeutics

ANTX stock →

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Cartesian Therapeutics

RNAC stock →

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

ANTX vs RNAC FAQ

Which is bigger, AN2 Therapeutics or Cartesian Therapeutics?

AN2 Therapeutics (ANTX) is larger, with a market capitalization of $192.75M compared with $187.29M for Cartesian Therapeutics (RNAC).

Which stock has performed better over the past year, ANTX or RNAC?

ANTX returned +366.06% over the past 12 months, compared with -15.19% for RNAC (price return, excluding dividends). Past performance does not predict future results.

Are AN2 Therapeutics and Cartesian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons